Natera, Inc. (NASDAQ:NTRA) Insider Sells $47,219.31 in Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) insider John Fesko sold 339 shares of the firm's stock in a transaction that occurred on Monday, July 21st. The shares were sold at an average price of $139.29, for a total transaction of $47,219.31. Following the completion of the transaction, the insider owned 153,460 shares in the company, valued at $21,375,443.40. The trade was a 0.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

John Fesko also recently made the following trade(s):

• On Tuesday, May 27th, John Fesko sold 1,438 shares of Natera stock. The shares were sold at an average price of $156.85, for a total value of $225,550.30.

Natera Stock Performance

Natera stock traded up $3.25 during mid-day trading on Thursday, reaching $141.07. The company's stock had a trading volume of 1,421,449 shares, compared to its average volume of 1,212,550. The business's 50 day simple moving average is $159.24 and its 200 day simple moving average is $157.55. The company has a market capitalization of $19.26 billion, a price-to-earnings ratio of -95.97 and a beta of 1.73. Natera, Inc. has a 12 month low of $92.14 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm's quarterly revenue was up 36.5% on a year-over-year basis. During the same period in the previous year, the company posted ($0.56) EPS. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analysts Forecast Growth

NTRA has been the subject of several research analyst reports. UBS Group increased their target price on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Piper Sandler increased their price objective on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Finally, Barclays upped their target price on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $184.63.

Institutional Investors Weigh In On Natera

Hedge funds have recently added to or reduced their stakes in the business. HighTower Advisors LLC boosted its position in Natera by 9.9% during the fourth quarter. HighTower Advisors LLC now owns 11,342 shares of the medical research company's stock valued at $1,795,000 after acquiring an additional 1,023 shares during the last quarter. Teacher Retirement System of Texas increased its holdings in shares of Natera by 37.9% during the fourth quarter. Teacher Retirement System of Texas now owns 43,693 shares of the medical research company's stock valued at $6,917,000 after acquiring an additional 11,999 shares in the last quarter. Quantbot Technologies LP acquired a new position in Natera during the 4th quarter valued at about $878,000. KLP Kapitalforvaltning AS bought a new position in shares of Natera in the fourth quarter valued at approximately $3,768,000. Finally, LPL Financial LLC grew its position in shares of Natera by 33.7% during the 4th quarter. LPL Financial LLC now owns 80,332 shares of the medical research company's stock valued at $12,717,000 after acquiring an additional 20,260 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.